Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 3/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.56 |
| ▸ | STS | P08842 | 2/20 | 0.52 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.50 |
| ▸ | CYP3A5 | P20815 | 2/20 | 0.50 |
| ▸ | HTT | P42858 | 2/20 | 0.49 |
| ▸ | NPC1 | O15118 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 1/20 | 0.49 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.49 |
| ▸ | RAB9A | P51151 | 1/20 | 0.49 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.49 |
| ▸ | MGLL | Q99685 | 2/20 | 0.48 |
| ▸ | ABHD6 | Q9BV23 | 1/20 | 0.48 |
| ▸ | GLS | O94925 | 1/20 | 0.47 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | CNR1 | P21554 | 3/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | VEGFA | P15692 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14128435 | 0.88 | GPR119 (0.50) | MEN1KMT2ACYP3A4CYP3A5HTT | |
| SCHEMBL1852622 | 0.88 | GLS (0.57) | MEN1KMT2ACYP3A4CYP3A5HTT | |
| SCHEMBL25083480 | 0.88 | MEN1 (0.54) | MEN1KMT2ASTSCYP3A4CYP3A5 | |
| SCHEMBL23532330 | 0.88 | MEN1 (0.54) | MEN1KMT2ASTSCYP3A4CYP3A5 | |
| SCHEMBL5183732 | 0.87 | MEN1 (0.49) | MEN1KMT2ACYP3A4CYP3A5HTT | |
| SCHEMBL23532403 | 0.86 | MEN1 (0.53) | MEN1KMT2ASTSCYP3A4CYP3A5 | |
| SCHEMBL19668434 | 0.86 | ALDH1A1 (0.55) | MEN1KMT2ASTSHTTNPC1 | |
| SCHEMBL4883412 | 0.86 | CYP3A4 (0.52) | MEN1KMT2ASTSCYP3A4CYP3A5 | |
| SCHEMBL17276580 | 0.85 | MGLL (0.64) | MEN1KMT2ASTSCYP3A4CYP3A5 | |
| SCHEMBL19668662 | 0.85 | MAPT (0.55) | CYP3A4CYP3A5HTTNPC1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230064189-A1 | 1H-PYRAZOLO[3,4-D]PYRIMIDINE COMPOUNDS USEFUL FOR THE TREATMENT OF PLATINUM-RESISTANT CANCER | IMPERIAL COLLEGE INNOVATIONS LIMITED (GB) | 2023-03-02 | — | — | US | disclosed |
| EP-4077329-A1 | 1H-PYRAZOLO[3,4-D]PYRIMIDINE COMPOUNDS USEFUL FOR THE TREATMENT OF PLATINUM-RESISTANT CANCER | Imperial College Innovations Limited (GB) | 2022-10-26 | — | — | EP | disclosed |
| WO-2021123798-A1 | 1H-PYRAZOLO[3,4-D]PYRIMIDINE COMPOUNDS USEFUL FOR THE TREATMENT OF PLATINUM-RESISTANT CANCER | IMPERIAL COLLEGE INNOVATIONS LIMITED (GB) | 2021-06-24 | — | — | WO | disclosed |
| US-7994172-B2 | [1-(3-bromo-1H-pyrazolo[3,4-d]pyrimidin-4-yl)piperidin-4-yl](4-chlorophenyl)methanol; kinase-dependent diseases, invasive cell growth, and metabolism | EXELIXIS, INC. (US) | 2011-08-09 | — | — | US | disclosed |
| US-7994172-B2 | [1-(3-bromo-1H-pyrazolo[3,4-d]pyrimidin-4-yl)piperidin-4-yl](4-chlorophenyl)methanol; kinase-dependent diseases, invasive cell growth, and metabolism | EXELIXIS, INC. (US) | 2011-08-09 | — | — | US | disclosed |
| US-20080188482-A1 | [1H-Pyrazolo[3, 4-D]Pyrimidin-4-Yl]-Piperidine or -Piperazine Compounds as Serine-Theoronine Kinase Modulators (P70s6k, Atk1 and Atk2) for the Treatment of Immunological, Inflammatory and Proliferative Diseases | EXELIXIS, INC. (US) | 2008-08-07 | — | — | US | disclosed |
| US-20080188482-A1 | [1H-Pyrazolo[3, 4-D]Pyrimidin-4-Yl]-Piperidine or -Piperazine Compounds as Serine-Theoronine Kinase Modulators (P70s6k, Atk1 and Atk2) for the Treatment of Immunological, Inflammatory and Proliferative Diseases | EXELIXIS, INC. (US) | 2008-08-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230064189-A1 | 1H-PYRAZOLO[3,4-D]PYRIMIDINE COMPOUNDS USEFUL FOR THE TREATMENT OF PLATINUM-RESISTANT CANCER | DPYD, ABCC1, TYMP | MEN1 1923/4885KMT2A 2582/4885STS 3011/4885 |
| US-20080188482-A1 | [1H-Pyrazolo[3, 4-D]Pyrimidin-4-Yl]-Piperidine or -Piperazine Compounds as Serine-Theoronine Kinase Modulators (P70s6k, Atk1 and Atk2) for the Treatment of Immunological, Inflammatory and Proliferative Diseases | PDPK1, MTOR, RPS6KA2 | MEN1 3071/4885KMT2A 3363/4885STS 2747/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.